Patent Yard Sign in
Canadian application, no grantCanada

Glutathione-s-lower fatty acid derivative

CA 2060209 A1 · Owner: Ohmori, Shinji · Inventors: Ogata, Kazumi; Sakaue, Takahiro; Ohmori, Shinji

CIPO record

Overview

Drawings and full text

Its claims, description and drawings are in the Canadian Patents Database.

Open the CIPO record

Abstract From the Canadian patent

An S-(lower fatty acid)-substituted glutathione derivative of general formula (I), salts thereof, and production thereof wherein , R1 represents hydrogen, R3 represents hydrogen or optionally substituted lower alkyl, R4 represents optionally substituted lower alkoxy or optionally substituted amino and n is 0 or 1, provided that when n is 1 R2 represents hydrogen, optionally, substituted lower alkyl or optionally substituted phenyl. These compounds can be advantageously used for treating hepatic disorders because they have an excellent activity of inhibiting these disorders.

Read the whole patent

Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.

Why it's free to use

  • Filed April 25, 1991. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 25, 2011.
  • A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 25, 2013.
  • We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledApril 25, 1991
GrantedNo grant recorded
Term endedApril 25, 2011
Patent numberCA 2060209 A1
Classification (IPC)C07K5/03 +2 more

Timeline

Timeline From CIPO dates

1992199419961998200020022004200620082010Application filedApril 25, 1991Term endedApril 25, 2011

Sources & verification

Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.